1 Long-term effects of directional deep brain stimulation in Parkinson's

2 disease: a randomized clinical trial on motor and non-motor 3 symptoms

4 Gharabaghi A^{1,2,3*}, Cebi I^{1,4}, Scherer M^{1,5}, Bookjans P¹, Brunnett B¹, Milosevic L^{1,5}, Weiss D⁴

5

6 1. Institute for Neuromodulation and Neurotechnology, University Hospital and7 University of Tübingen, 72076 Tübingen, Germany

8 2. Center for Bionic Intelligence Tübingen Stuttgart (BITS), 72076 Tübingen, Germany

9 3. German Center for Mental Health (DZPG), 72076 Tübingen, Germany

4. Center for Neurology, Department for Neurodegenerative Diseases, and Hertie
 Institute for Clinical Brain Research, University Tübingen, 72076 Tübingen, Germany

12 5. Clinical and Computational Neuroscience, Krembil Research Institute, University
13 Health Network, M5T 2S8 11 Toronto, Canada.

14

*Corresponding author: Prof. Alireza Gharabaghi. Address: Institute for
Neuromodulation and Neurotechnology, University Hospital Tübingen, Otfried-MüllerStr. 45, 72076 Tübingen, Germany. Email: alireza.gharabaghi@uni-tuebingen.de

18

Key words: Deep brain stimulation; directional steering; segmented contacts; ringcontacts; circular contacts; long-term effects.

22 Abstract

- 23 Background
- 24 Deep brain stimulation (DBS) of the subthalamic nucleus (STN) in Parkinson's disease
- (PD) that is more precisely focused to the desired target structure may avoid nearby
- 26 structures that are responsible for undesired side effects.
- 27 Objective
- 28 Comparing the long-term effects of STN-DBS with segmented or ring contacts on motor
- and non-motor symptoms in akinetic-rigid PD patients.
- 30 Methods

This study was a prospective randomized clinical trial. At 6-months postoperatively, the optimal omnidirectional (OS) and directional (DS) stimulation contacts were compared in MedOFF within a double-blind cross-over design, both acutely (within one day) and chronically, i.e., after 3-week stimulation blocks of each condition. The examination included motor and non-motor evaluations (e.g., cognition, mood and quality of life). Importantly, the stimulation intensity of the optimal DS was adjusted such that the total electrical energy delivered (TEED) was equivalent to the TEED of the optimal OS.

38 Results

There were no significant differences between OS and DS with regard to all outcome parameters, with 30% less stimulation intensity of the latter. Notably, OS scored (nonsignificantly) better than DS in all motor and non-motor measures apart from the cognitive evaluation, where OS led to a deterioration of executive functions. However, in 3 of 19 patients, the stimulation intensity of DS needed to be increased above the TEED-estimated values to reach the motor benefits of OS.

45 Conclusions

Reliable comparisons between OS and DS require long-term clinical evaluations. A
potential differential influence on motor and non-motor symptoms needs to be
investigated in future confirmatory studies.

49 Registration: ClinicalTrials.gov: NCT03548506

50 Introduction

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an evidence-based 51 and cost-effective therapy for idiopathic Parkinson's disease (PD) patients, with superior 52 motor, non-motor and quality of life outcomes compared to the best medical therapy 53 once dopaminergic response fluctuations occur (1-7). The greatest therapeutic 54 effectiveness of DBS is often achieved in the motor part of the STN and its immediate 55 surrounding (8). However, the spread of the stimulation current into nearby structures 56 can also lead to side effects such as muscle contractions, paresthesia, postural 57 instability, speech impairment, reduced verbal fluency, involuntary eye movements, and 58 impaired cognition (9-11). Among them, motor-related side effects (e.g., muscle 59 60 contractions) are usually immediately detected and can often be addressed with 61 adjusting the stimulation parameters. However, when they occur at low stimulation intensities, which are insufficient to achieve the therapeutic benefits, and when 62 reprogramming cannot resolve the condition, subsequent surgery for lead revision may 63 be necessary (12). In contrast, non-motor side effects (e.g., cognitive impairment) are 64 65 often less apparent and remain undetected, when searching for optimal stimulation parameters in the acute setting. 66

Technological progress of the implanted stimulation hardware has raised new hope to 67 overcome current limitations. Specifically, in the new generation of electrodes, the 68 middle two of the usually four ring contacts are divided into three segments each. This 69 70 makes it possible, in addition to circular/omnidirectional stimulation (OS) in the conventional ring mode, to also focus the stimulation field more precisely in the 71 horizontal plane around one or two electrode segments with directional stimulation 72 steering (DS). In this context, previous studies have investigated, both intraoperatively 73 (13, 14) and extraoperatively (7, 15-17), the therapeutic windows of DS and OS, i.e., the 74 range between the stimulation amplitude that first produces beneficial effects and the 75 stimulation amplitude that first produces side effects. An increased therapeutic window 76 of DS vs. OS has often been reported during these acute evaluations, thus suggesting 77 that DS away from the structures causing side effects is in principle possible. Whether 78 79 these gains are also clinically relevant in the long-term, e.g., by compensating for

suboptimal electrode placements and reducing the necessity for revision surgery, is still 80 an open question. Despite a considerable evolution of image-guided neurosurgical 81 targeting methods (18, 19), refined intraoperative techniques (20, 21), awake 82 procedures (22) and novel stimulation paradigms (23), the side effects and/or 83 insufficient therapeutic benefits may lead to revision surgery in up to 15-30% of patients 84 (12). A simulation study, for example, suggests that DS reduces out-of-target 85 stimulation (that would lead to side effects), but is limited in achieving the target volume 86 87 (for maximum therapeutic benefit), when compensating for suboptimal electrode placements with a shift of more than 1 mm (24). Moreover, a recent study revealed that 88 six of 42 patients (i.e., ten of 72 leads) required surgical revision owing to electrode 89 malposition despite the ability to steer the current with DS to relieve stimulation-induced 90 91 side effects (25). This may suggest that the frequently described improvements in surrogate parameters such as the therapeutic window do not regularly translate into 92 93 clinical benefits (26).

On this basis, it is of particular relevance to determine the potential of DS to improve the 94 therapeutic precision in the majority of patients with well-placed electrode leads where 95 beneficial therapeutic effects can be achieved without acute side effects. For these 96 97 cases, it is unknown as to whether DS allows for a more efficient stimulation of the target structure, e.g., by lowering the stimulation intensity required to achieve the 98 desired clinical benefit, also for longer observation periods beyond acute assessments. 99 Such long-term assessments would allow to estimate potential benefits of DS also with 100 regard to non-motor side effects, e.g., cognitive impairment. 101

102 In this context, an important consideration is that therapeutic impedance and surface current density are dependent on the electrode surface, and systematically differ 103 104 between larger ring and smaller segmented contact sizes; associated with greater current density of the latter (27). It has therefore been suggested that stimulation 105 106 intensity adjustments using DS should be performed using smaller amplitude increments (i.e., 0.1–0.3 mA compared to the traditional 0.5 mA). Moreover, it needs to 107 108 be considered that because of the higher impedance (1.8-2.2 times that of standard ring contacts) due to the smaller stimulating surface of segmented contacts, stimulation at a 109

particular intensity is associated with a greater total electrical energy delivered (TEED) 110 when using DS compared to OS. As such, these settings would impose a greater 111 energy burden and quicken battery consumption; which is an important factor 112 influencing the frequency of subsequent surgical procedures for battery replacement. 113 Already an 18% increase from the average TEED with DS vs. OS, would lead to as 114 much as a year of battery lifespan lost ⁴⁵. Therefore, the desired stimulation effects need 115 to be achieved with at least the same TEED, i.e., about 30% lower stimulation 116 117 amplitudes of DS vs. OS, to avoid a negative influence on the battery lifespan (28). These aspects need to be considered when aiming for overall improvements of clinical 118 care. Moreover, the stimulation effects in previous studies were only recorded clinically 119 using an ordinal scale (i.e., the Unified Parkinson's Disease Ratings Scale; UPDRS) 120 121 and were therefore dependent on subjective assessments of the symptoms.


122 We have therefore designed a study to systematically compare the efficacy of DS vs. 123 OS in the context of a prospective, randomized, double-blind, crossover clinical trial, taking the aforementioned considerations into account. Namely, (i) applying - in 124 addition to clinical measures - also an objective and ratio-scaled measure, i.e., 125 electromyography (EMG) (29) to assess muscular rigidity; (ii) conducting stimulation 126 127 titration at each contact with small increments in stimulation intensity (0.2 mA steps) for both stimulation conditions; (iii) maintaining TEED between DS and OS; (iv) applying 128 the randomized, double-blinded evaluations after both acute and chronic stimulation 129 periods; and (v) assessing both motor and non-motor symptoms. We tested the 130 hypothesis that, even under these rigorously controlled conditions, the focused 131 stimulation of the target structure with DS could achieve similar therapeutic efficacy on 132 motor symptoms while reducing non-motor side effects. 133

134

135 Methods

136 Patients

All patients who participated in this study were nominated for deep brain stimulation 137 surgery upon multidisciplinary review based on standard inclusion/exclusion criteria for 138 STN-DBS in PD (30), independent from study participation. The study was approved by 139 the ethics committee of the Medical Faculty of the University of Tuebingen. Twenty-140 three consecutive akinetic-rigid patients scheduled for STN-DBS were included in this 141 study after providing written informed consent to participation. Four patients dropped out 142 due to personal reasons not related to the study. Nine-teen patients completed the 143 study with the cross-over treatment evaluation periods. Participant and drop-out 144 numbers at each phase of the study are summarized in Figure. 1. Patient demographics 145 146 are summarized in Table 1.



148 Figure 1: Consort flow diagram of the SANTOP study

ID	Sex/	Age	Disease	LEED	Stimulation	Stimulation
	gender	(years)	duration	(mg/d)	parameters Omnidirectional	parameters Directional
			(years)		Ommunicetional	Directional
			(years)			
1	m	60s	10-15	1000-1250	L 3- G+ 2.1mA 60µs 130Hz	L 3C- G+ 1.4mA 60µs 130Hz
					R 11- G+ 3.7mA 60μs 130Hz	R 11B- G+ 2.3mA 60µs 130Hz
2*	f	60s	10-15	750-1000	L 3- G+ 3.3mA 60µs 130Hz	L 3A- G+ 2.5mA 60µs 130Hz
					R 11- G+ 3.5mA 60µs 130Hz	R 11C- G+ 2.5mA 60µs 130Hz
3	m	50s	10-15	1000-1250	L 3- G+ 1.3mA 60µs 130Hz	L 3C- G+ 0.5mA 60µs 130Hz
					R 11- G+ 2.3mA 60µs 130Hz	R 11A- G+ 1.2mA 60µs 130Hz
4*	m	70s	10-15	250-500	L 3- G+ 2.70mA 60µs 130Hz	L 3A- G+ 2.2mA 60µs 130Hz
					R 11- G+ 2.20mA 60μs 130Hz	R 11A- G+ 2.0mA 60µs 130Hz
5	m	50s	5-10	1000-1250	L 3- G+ 1.5mA 60µs 130Hz	L 3A- G+ 0.95mA 60µs 130Hz
					R 11- G+ 1.5mA 60µs 130Hz	R 11C- G+ 1.05mA 60µs 130Hz
6	m	50s	5-10	1250-1500	L 3- G+ 0.8mA 60µs 130Hz	L 3A- G+ 0.55mA 60µs 130Hz
					R 11- G+ 4.5mA 60µs 130Hz	R 11A- G+ 3.1mA 60µs 130Hz
7	m	40s	10-15	1250-1500	L 3- G+ 1.6mA 60µs 130Hz	L 3A- G+ 1.25mA 60µs 130Hz
					R 11- G+ 3.7mA 60µs 130Hz	R 11B- G+ 2.85mA 60µs 130Hz
8*	f	60s	10-15	750-1000	L 3- G+ 2.2mA 60µs 130Hz	L 3A- G+ 1.8mA 60µs 130Hz
					R 11- G+ 4.0mA 60µs 130Hz	R 11C- G+ 2.7mA 60µs 130Hz
9	f	50	10-15	250-500	L 3- G+ 2.8mA 60µs 130Hz	L 3A- G+ 2.05mA 60µs 130Hz
					R 11- G+ 2.9mA 60µs 130Hz	R 11B- G+ 1.95mA 60µs 130Hz
10	f	70s	10-15	500-750	L 3- G+ 4.7mA 60µs 130Hz	L 3B- G+ 3.35mA 60µs 130Hz
					R 11- G+ 4.7mA 60µs 130Hz	R 11B- G+ 3.35mA 60µs 130Hz
11	f	50s	15-20	500-750	L 3- G+ 1.1mA 60µs 130Hz	L 3B- G+ 0.75mA 60µs 130Hz
					R 11- G+ 1.5mA 60µs 130Hz	R 11C- G+ 1.00mA 60µs 130Hz
12	m	60s	5-10	250-500	L 3- G+ 2.7mA 60µs 130Hz	L 3C- G+ 2.6mA 60µs 130Hz
					R 11- G+ 2.8mA 60µs 130Hz	R 11A- G+ 1.95mA 60µs 130Hz
13	m	70s	10-15	1000-1250	L 3- G+ 2.5mA 60µs 130Hz	L 3B- G+ 1.7mA 60µs 130Hz
					R 11- G+ 2.7mA 60µs 130Hz	R 11B- G+ 1.85mA 60µs 130Hz
14	m	70s	5-10	750-1000	L 3- G+ 3.0mA 60µs 130Hz	L 3C- G+ 2.1mA 60µs 130Hz
					R 11- G+ 2.8mA 60µs 130Hz	R 11A- G+ 1.8mA 60µs 130Hz
15	m	60s	10-15	750-1000	L 2- G+ 1.7mA 60µs 130Hz	L 2C- G+ 1.1mA 60µs 130Hz
					R 10- G+ 2.2mA 60µs 130Hz	R 10B- G+ 1.4mA 60µs 130Hz
16	m	60s	15-20	750-1000	L 3- G+ 2.8mA 60µs 130Hz	L 3B- G+ 2.1mA 60µs 130Hz
					R 11- G+ 3.3mA 60µs 130Hz	R 11B- G+ 2.3mA 60µs 130Hz
17	f	50s	5-10	500-750	L 3- G+ 2.3mA 60µs 130Hz	L 3C- G+ 1.65mA 60µs 130Hz
					R 11- G+ 2.1mA 60µs 130Hz	R 11C- G+ 1.5mA 60µs 130Hz
18	m	50s	5-10	750-1000	L 3- G+ 2.7mA 60µs 130Hz	L 3A- G+ 1.9mA 60µs 130Hz
					R 11- G+ 0.9mA 60µs 130Hz	R 11B- G+ 0.5mA 60µs 130Hz
19	m	60s	10-15	1000-1250	L 3- G+ 2.7mA 60µs 130Hz	L 3C- G+ 1.8mA 60µs 130Hz
					R 11- G+ 2.5mA 60μs 130Hz	R 11C- G+ 1.7mA 60µs 130Hz

149

Table 1: Patient demographics and stimulation parameters are summarized in. LEED indicates the levodopa equivalent dose during the cross-over-phase. The asterisk "*" indicates patients in whom a reprogramming was necessary during the cross-overphase: ID2: the calculated directional stimulation was L 3A- G+ 2.1mA 60µs 130Hz, R

11C- G+ 2.2mA 60µs 130Hz; patient reported bradykinesia and had rigidity and freezing
 of gait with directional stimulation during the cross-over-phase so that we needed to
 increase the stimulation Intensity.

155 *ID4:* the calculated directional stimulation was L 3A- G+ 1.85mA 60μs 130Hz, R 11A-156 G+ 1.55mA 60μs 130Hz; patient reported bradykinesia and had rigidity with directional 157 stimulation during the cross-over-phase so that we needed to increase the stimulation 158 intensity.

ID8: the calculated directional stimulation was L 3A- G+ 1.6mA 60µs 130Hz, R 11C- G+ 2.6mA 60µs 130Hz; patient reported worsening of motor fluctuations so that we needed to increase the stimulation intensity.

162

163 Surgical procedure

The tentative implantation location in each hemisphere was initially determined by 164 conventional image-based direct targeting of the STN using preoperative MRI (T2-165 weighted and/or SWI) (31). Patients were withdrawn from antiparkinsonian medications 166 overnight, and on the day of surgery electrophysiological recordings of single-unit 167 168 and/or local field potential activities were used to confirm the target location in each hemisphere. Initially, single unit recordings were used to delineate STN entry and 169 spatial extent by characteristic burst firing rates (20-60 Hz) and irregular or bursting 170 patterns (32). The trajectory yielding greatest spatial extent of STN was then selected 171 for the DBS electrode implant. The final position of the DBS electrode was once again 172 titrated using neurophysiological recordings directly from the DBS contacts, such that 173 two levels of the DBS lead containing segmented contacts were placed in the area of 174 STN yielding greatest beta (13-30 Hz) oscillatory power, determined by (online) 175 intraoperative power spectral density calculations (21). There were no complications 176 from surgical procedures. 177

178 Study design

This study was a prospective, randomized, double-blind, crossover, single-center clinical trial, i.e., the SANTOP (Subthalamic steering for therapy optimization in Parkinson's Disease) study (preregistered at ClinicalTrials.gov: NCT03548506). The

comprehensive study design is illustrated as Figure 1. The patients were enrolled 182 preoperatively (V0). The postoperative visits started 2-months (V1/2) and 6-months 183 (V3/4/5) after surgery. All evaluations were done in the Med OFF condition after 184 overnight withdrawal of dopaminergic medication. The patients and the evaluators were 185 blinded to stimulation conditions during the whole study. At the 2-months visits, a 186 monopolar review was performed on two subsequent days to identify the optimal 187 contact and stimulation parameters for omnidirectional (V1) and directional (V2) 188 stimulation. 189

At the 6-months visit (V3), OS and DS were compared to each other and to Stim OFF in 190 191 randomized order, i.e., 30 minutes from reprogramming for each condition (acute setting). Afterwards, stimulation settings were randomized again for a three-week 192 193 (chronic setting) active treatment period (by a study coordinator who would not be involved in clinical evaluation) to either the omnidirectional settings, or the energy-194 195 equivalent directional settings (preconfigured options in the stimulation programmer). After the first three-week treatment period (V4), blinded collection of outcome data 196 (described below) was performed by a clinician, followed by a cross-over in stimulation 197 settings performed by a study coordinator. After another 3-week treatment period (V5). 198 199 blinded outcome data were collected once more. This procedure allowed to directly compare OS and DS after long-term stimulation periods, during which other parameters 200 (such as medication) were kept unchanged. These study epochs are summarized in 201 Figure 1. 202

203 Identification of optimal contact and stimulation parameters

At 2-months (on average 67 days, +/- 9 days, range 56-88 days) postoperatively (see Figure 1), stimulation titration was performed on two subsequent days after overnight withdrawal from medication. On the first day (V1), each patient underwent a monopolar review of the three upper contacts using circular stimulation at each level to determine the optimal OS level. On the second day (V2), the same procedure was repeated using the three segmented contacts of the previously determined best omnidirectional level (V1) to determine the optimal stimulation direction.

During these visits, rigidity in the contralateral upper limb was assessed (double-blind) 211 by a clinician during unilateral stimulation, while the programming and random electrode 212 contact selection was conducted by another examiner at a stimulation frequency of 213 130 Hz and a pulse width 60 µs, using intensities starting from 0.5 mA and 214 incrementally increasing by 0.2 mA, until a (self-reported) side effect threshold was 215 reached. At each stimulation increment, a 1-minute rigidity assessment (consisting of 216 passive movements of the upper limb by flexing and extending the elbow) was 217 218 performed to determine the effect threshold.

The therapeutic window was determined for each evaluated contact, and the contact 219 220 with the greatest therapeutic window and/or best effect threshold in each hemisphere was considered optimal. The stimulation intensity for each optimal segmented contact 221 222 was then determined by titration of the stimulation intensity such that the total electrical energy delivered (33) was equivalent to the total electrical energy of the optimal 223 224 omnidirectional settings. Of note, the stimulation intensity for DS was always lower than for OS due to the greater impedance associated with a smaller stimulation surface (see 225 also the Introduction). The OS and DS parameters for each patient are available in 226 Table 1. 227

228 Treatment evaluation and outcome measures

229 At a minimum of 6-months (on average 229 days, +/- 46 days, range 187-369 days) postoperatively (see Figure 1), OS and DS were compared to each other in an acute 230 231 (V3) and chronic setting (V4/5). The muscle rigidity of the upper extremity was measured by means of surface EMG recording (BrainAmp DC/EXG, Brain Products, 232 Munich, Germany; sampled at 5 kHz) of the M. biceps brachii and the M. triceps brachii. 233 Previous work suggests that the EMG profile during standardized passive extension and 234 235 flexion movements of the elbow joint is influenced by DBS and corresponds with standardized clinical scales (29). The evaluation procedure consisted of EMG recording 236 during a 30-second non-movement period, followed by a 60-second period of passive 237 flexion/extension (~0.5 Hz cycles) of the elbow (~90°). Five trials of this procedure were 238 performed for each arm at each stimulation intensity and each electrode contact. 239

At both V3 and V4/5, the following data was collected: MDS-UPDRS parts III (34); timed 240 Capsit-PD walking test (35); Freezing of Gait Assessment Course (FoG-AC) (36); 241 Spatial (SDR) (37) and verbal (VDR) (38) working memory with respective visual (39) 242 and acoustic odd-ball tests (40) for attention monitoring, and task-related EEG 243 recordings (41). During the acute V3 assessment, no stimulation (STIM OFF), 244 directional and omnidirectional settings were compared in randomized order. During the 245 chronic V4/5 cross-over assessment, directional and omnidirectional settings were 246 247 compared in randomized order.

At V4/5, this additional data was acquired: MDS-UPDRS part I, II and IV (34); Parkinson's Disease Quality of Life Scale (PDQ-39) (42); Becks 'Depression Inventory (BDI) (43); Montreal Cognitive Assessment (MoCA) (44); Apathy Scale (45); Lille Apathy rating scale (46); Deep Brain Stimulation impairment scale (DBS-IS) (47).

252 EMG data processing and analysis

EMG data processing consisted of artifact rejection, epoching, feature extraction and, 253 254 faulty trial rejection. Initially, the stimulation artifact, the line noise, and their respective harmonics were removed from the data. After artifacts had been removed, the data 255 were split into epochs. From each run, two segments were extracted, a 30-second non-256 movement segment and a 30-second movement segment. These segments were 257 258 further divided into individual 2-second epochs. While strict 2-second cutting was applied to the non-movement phase data, the movement phase data were cut according 259 260 to full movement cycles (0.5 Hz). To extract feature information from the EMG signal, 261 the signal was detrended, and enveloped via the absolute of the Hilbert transform. The average amplitude (power) of the signal was extracted as feature information and was 262 then normalized with respect to the overall EMG power between 2 and 300 Hz to 263 264 account for different impedance levels across recordings. Finally, outliers on a feature 265 level were rejected if z-score > 2 (i.e., more than two standard deviations from the mean). 266

EMG data was analyzed using generalized linear mixed models (glmm). Factors modeled in the analysis were as follows: "counter-movement" to evaluate the effect of the counter-movement on the EMG power; the "stimulation-condition:" to contrast DS

and OS modes; "movement" to contrast between rest versus passive movement phases in EMG activity; the interaction between the stimulation-condition and movement; the (chronologically ordered) "recording id" to compensate for repeated measurements over time; "trial id" to compensate for repeated measurements within trials; "patient id" as a random factor to compensate for repeated measurements across patients. Secondary outcome data of standardized clinical score assessments were assessed using paired Wilcoxon signed-rank tests to compare stimulation conditions.

277 **Results**

At 6-months postoperatively, optimal ring and segmented contacts were compared to 278 each other with average TEED-adapted stimulation intensities of 2.59 ± 0.77 mA for OS 279 and 1.82 ± 0.61 mA for DS; this was equivalent to a difference of 30.37 ± 8.47 %. First, 280 OS and DS were compared to each other and to Stim OFF in randomized, cross-over 281 order in an acute setting (V3), i.e., 30 min after reprogramming within the same day. 282 After this acute assessment, OS and DS were compared to each other in randomized, 283 cross-over order in a chronic/long-term setting, i.e., 3 weeks after reprogramming for 284 each condition (V4/5). 285

286 Motor symptoms

In the acute setting (V3), both conditions had similar therapeutic efficacy on motor 287 symptoms, i.e., there was no significant difference between OS and DS (Table 2). 288 Specifically, OS (30.00 ± 13.55; p=.001) and DS (30.72 ± 10.87; p=.003) improved 289 290 UPDRS III as compared to Stim OFF (39.63 ± 12.92); also, the FoG-AC improved with both OS (14.83 ± 13.66; p=.021) and DS (13.92 ±13.32; p=.024) as compared to Stim 291 OFF (17.83 ± 15.05). There were, however, no significant differences between OS and 292 DS for UPDRS III (p=.521) and FoG-AC (p=.591), or the other outcome measures 293 including the oddball and working memory tasks (VDR/SDR). 294

	Scores				Wilcoxon signed-rank test							
	Omnidirectional	Directional	Stim Off	Stim Off vs Omnidirectional		Stim Off vs			Omnidirectional vs			
						Directional		Directional				
	Mean ±SD/	Mean ±SD/	Mean ±SD/	p-value	z-value	n	p-value	z-value	n	p-value	z-value	n
	Median [min max]	Median [min max]	Median [min max]									
MDS-UPDRS III	30.00 ± 13.55	30.72 ± 10.87	39.63 ± 12.92	0.001	-3.298	15	0.003	-2.985	15	0.521	-0.641	17
VDR												
Task accuracy	0.71 ± 0.27	0.69 ± 0.27	0.65 ± 0.31	0.181	-1.338	15	0.440	-0.772	16	0.860	-0.176	16
Task reaction time	2.56 ± 0.63	2.51 ± 0.59	2.56 ± 0.38	0.379	-0.879	14	0.532	-0.625	15	0.925	-0.094	15
Oddball accuracy	0.94 ± 0.07	0.90 ± 0.21	0.89 ± 0.17	0.676	-0.418	15	1.000	0.000	16	0.324	-0.986	16
Oddball reaction time	0.92 ± 0.23	0.90 ± 0.26	1.18 ± 0.51	0.061	-1.875	15	0.002	-3.131	16	0.227	-1.087	16
SDR												
Task accuracy	0.27 ± 0.10	0.30 ± 0.07	0.29 ± 0.08	0.553	-0.593	15	0.288	-1.063	14	0.475	-0.714	15
Task reaction time	1.76 ± 0.78	1.73 ± 0.60	1.80 ± 0.68	1.000	0.000	15	0.925	-0.094	14	0.532	-0.625	15
Oddball accuracy	0.64 ± 0.22	0.64 ± 0.21	0.65 ±0.23	0.864	-0.171	15	0.861	-0.175	14	0.527	-0.633	15
Oddball reaction time	1.04 ± 0.41	1.04 ± 0.34	1.11 ± 0.42	0.826	-0.220	14	0.363	-0.910	14	0.875	-0.157	14
FoG-AC	14.83 ± 13.66	13.92 ±13.32	17.83 ± 15.05	0.021	-2.307	12	0.024	-2.251	12	0.591	-0538	12
CAPSIT												
Steps	38.36 ± 22.26	43.50 ± 33.56	38.75 ±26.29	0.119	-1.561	12	0.285	-1.069	12	0.166	-1.385	14
Time (s)	33.07 ± 43.95	37.86 ± 58.97	37.58 ± 51.46	0.073	-1.795	12	0.349	-0.936	12	0.244	-1.166	14
Freezing episodes	0.93 ± 1.73	2.50 ± 5.97	1.67 ± 3.42	0.273	-1.095	12	1.000	0.000	12	0.225	-1.214	14

Table 2: Six months after surgery (V3), both conditions (OS and DS) had significant therapeutic efficacy with regard to segmental (MDS-UPDRS III) and axial motor (FOG-AC) symptoms compared to Stim Off during the acute evaluation (i.e., 30 min stimulation periods); however, there were no significant differences between the omnidirectional (OS) and directional (DS) conditions.

In the *long-term setting* (V4/5), both conditions had also similar therapeutic efficacy, i.e., there were no significant differences between OS and DS with regard to motor symptoms (Table 3) and EMG-based assessments ($p \ge .135$). However, in 3 of the 19 patients (i.e., 15.79%), stimulation amplitudes had to be increased for the DS condition (above and beyond the estimated TEED) to achieve the therapeutic current strength, i.e., to avoid motor fluctuations, bradykinesia, rigidity and freezing of gait (for further details see the legend of Table 1).

Notably, OS scored (non-significantly) better than DS for UPDRS III (28.63 ± 12.91 vs. 308 32.42 ± 15.07), FoG (11.47 ± 13.02 vs. 12.80 ± 13.80), CAPSIT steps (39.11 ± 20.55 309 vs. 42.00 ± 22.02), CAPSIT time (27.44 ± 23.74 vs. 31.82 ± 34.04), and PDQ-39 310 Mobility (19.22 ± 10.73 vs. 21.13 ± 8.16). Moreover, long-term stimulation (i.e., 311 evaluation after 3-week blocks, V4/5) changed the scores in comparison to the acute 312 evaluation (i.e., evaluation after 30 min, V3); specifically, the UPDRS III score improved 313 from 30.00 ± 13.55 to 28.63 ± 12.91 for OS, and deteriorated from 30.72 ± 10.87 to 314 315 32.42 ± 15.07 for DS.

316 Non-motor symptoms

In the long-term setting (V4/5), there were no significant differences between OS and 317 DS with regard to non-motor symptoms (Table 3). Notably, OS scored (non-318 319 significantly) better than DS on all (BDI, AS, DBS-IS, LARS, PDQ-39) but one nonmotor clinical measure. The only non-motor clinical measure favoring DS was the 320 MOCA evaluation; specifically, OS led to (non-significantly) more cognitive impairment, 321 i.e., a lower MOCA score as compared to DS (26.53 \pm 3.15 vs. 27.83 \pm 1.92; p=.080). 322 This effect was driven by a deterioration of the MOCA sub-score for executive functions 323 (OS vs. DS: 3.89 ± 1.05 vs. 4.47 ± 0.84; p=.071; OS vs. preoperative baseline: 3.89 ± 324 1.05 vs. 4.63 ± 0.60; p=.015). 325

	Sco	ores	Wilcoxon signed-rank test				
	Omnidirectional Directional		Omnidirectional vs Directional				
	Mean ±SD/	Mean ±SD/	p-value	z-value	n		
	Median [min max]	Median [min max]					
MDS-UPDRS I	11.16 ± 8.49	11.00 ± 5.94	0.909	-0.114	17		
MDS-UPDRS II	18.16 ± 9.32	19.06 ± 9.19	0.568	-0.571	18		
MDS-UPDRS III	28.63 ± 12.91	32.42± 15.07	0.121	-1.550	19		
MDS-UPDRS IV	8.17 ± 4.89	8.78 ± 4.45	0.925	-0.095	17		
VDR					-		
Task accuracy	0.70 ± 0.29	0.69 ± 0.23	1.000	0.000	17		
Task reaction time	2.56 ± 0.51	2.54 ± 0.59	0.845	-0.196	18		
Oddball accuracy	0.96 ± 0.08	0.94 ± 0.11	0.271	-1.100	18		
Oddball reaction time	0.91 ± 0.32	0.85 ± 0.27	0.267	-1.111	18		
SDR				•			
Task accuracy	0.25 ± 0.12	0.22 ± 0.09	0.355	-0.924	17		
Task reaction time	1.83 ± 0.64	1.71 ± 0.53	0.918	-0.103	16		
Oddball accuracy	0.64 ± 0.26	0.57 ± 0.26	0.265	-1.115	17		
Oddball reaction time	1.09 ± 0.35	1.01 ± 0.33	0.469	-0.724	16		
FoG-AC	11.47 ± 13.02	12.80 ± 13.80	0.129	-1.517	15		
CAPSIT							
Steps	39.11 ± 20.55	42.00 ± 22.02	0.072	-1.801	17		
Time (s)	27.44 ± 23.74	31.82 ±34.04	0.142	-1.468	17		
Freezing episodes	1.56 ± 3.75	1.53 ± 3.63	0.131	-1.511	17		
MOCA	26.53 ± 3.15	27.83 ± 1.92	0.080	-1.753	17		
Executive	3.89 ± 1.05	4.47 ± 0.84	0.071	-1.805	19		
Naming	2.84 ± 0.69	3.00 ± 0.00	0.317	-1.000	18		
Attention	5.58 ± 0.69	5.44 ± 0.86	0.206	-1.265	18		
Language	2.44 ± 0.62	2.32 ± 0.82	0.366	-0.905	18		
Abstraction	1.89 ± 0.32	2.00 ± 0.00	0.157	-1.414	18		
Delayed Recall	3.95 ± 1.31	4.37 ± 0.83	0.323	-0.988	19		
Orientation	5.95 ± 0.23	6.00 ± 0.00	0.317	-1.000	19		
BDI	13.56 ± 7.25	14.88 ±6.91	0.448	-0.758	17		
AS	16.11 ±4.58	17.58 ±4.49	0.646	-0.406	16		
DBS-IS	25.94 ± 14.61	28.06 ±12.52	0.674	-0.421	17		
LARS	-22.47 ± 7.33	-20.61 ± 10.14	0.275	-1.091	18		
PDQ 39			•				
Mobility	19.22 ± 10.73	21.13 ± 8.16	0.380	-0.877	15		
Activities of daily living	9.06 ± 5.68	9.72 ± 5.06	1.000	0.000	17		
Emotions	8.06 ± 4.56	9.00 ± 4.04	0.318	-0.999	17		
Stigma	3.50 ± 3.24	4.39 ± 2.43	0.304	-1.027	17		
Social support	1.94 ± 2.31	2.53 ± 2.27	0.094	-1.672	17		
Cognition	5.00 ± 3.27	6.38 ± 2.90	0.477	-0.711	15		
Communication	4.06 ± 3.42	4.53 ± 2.74	0.832	-0.212	16		
Bodily discomfort	5.11± 2.61	5.35 ± 2.34	0.640	-0.467	16		

326

Table 3: Six months after surgery, in the cross-over period (V4/5), there were no significant differences between OS and DS with regard to motor and non-motor

symptoms during the chronic evaluation (i.e., after 3-week stimulation blocks of each condition).

331 **Discussion**

This study determined the potential of directional stimulation steering (DS) with 332 segmented contacts to improve the therapeutic precision of STN-DBS. Specifically, and 333 334 in contrast to previous work, we investigated whether DS allowed for a more efficient stimulation of the target structure by lowering the stimulation intensity required to 335 achieve the clinical benefit with regard to motor symptoms. For this purpose, the study 336 had unique methodological features: The optimal contacts were identified by conducting 337 338 the stimulation titration with small increments in stimulation intensity (0.2 mA steps) for both OS and DS: the TEED was maintained between OS and DS for longer observation 339 340 periods beyond acute assessments in a cross-over design; thereby, also non-motor 341 symptoms, e.g., cognitive impairment, could be assessed. By that, this study revealed that there were no significant differences between OS and DS with regard to all 342 outcome parameters, with 30% less stimulation intensity of the latter. Whether the more 343 focused stimulation of the target structure with DS will also achieve fewer side effects, 344 345 e.g., with regard to executive functions, needs to be investigated in confirmatory studies, since this exploratory approach could potentially be affected by multiple 346 comparisons. 347

Currently, there are few systematic studies comparing directional STN-DBS to standard 348 omnidirectional stimulation which include intra- and extra-operative assessments. One 349 intraoperative study (14) demonstrated a larger therapeutic window with DS, i.e., an 350 351 increase of the distance between the clinical effect threshold (i.e., minimum stimulation intensity to elicit a beneficial effect) and the side effect threshold (i.e., minimum 352 353 stimulation intensity to elicit side effects). However, another intraoperative study (13) did not demonstrate any relevant increases of the therapeutic window with DS compared to 354 355 conventional OS. Two extraoperative studies (one retrospective, open-label pilot study (16), and one prospective, randomized and double-blind study (15)) found an increase 356 in the side effect threshold, but no decrease in the clinical effect threshold (i.e., 357 therapeutic current strength); while another extraoperative retrospective, open-label 358

case series showed a decrease also of the clinical effect threshold with directional 359 programming (48). However, the clinical evaluations in this latter study were conducted 360 with different step-sizes of the applied stimulation amplitudes, i.e., 0.5 mA for OS and 361 0.1-0.2 mA for DS, which considers the higher charge density of the latter, but may also 362 bias the findings with regard to the sensitivity for clinical effect and side effect threshold 363 detection. An accurate thresholding with the same amplitude step-sizes for both 364 stimulation conditions is an important prerequisite for detecting improved therapeutic 365 366 effectiveness of one approach or the other. Furthermore, relevant differences between the various segmented stimulation directions could be found with regards to the side 367 effect threshold (16), but not with regard to the therapeutic effectiveness (14). Possible 368 reasons for these variable findings are: (i) different accuracies in titration of the 369 370 stimulation amplitude (in previous extraoperative studies, the systematic titration of the stimulation amplitude was carried out in steps of 0.5 mA (16) or 1.0 mA (15), whereas 371 372 Pollo and colleagues (14) chose 0.1 mA steps for their intraoperative examinations); (ii) stimulation effects were recorded clinically and on an ordinal scale (i.e. UPDRSIII) and 373 374 were therefore dependent on a subjective assessment of the symptoms and the experience of the examiner. 375

376 The most comprehensive investigation to date is the prospective, randomized, doubleblind PROGRESS multicenter study (17). The primary endpoint was evaluated acutely 377 three months after initial programming by demonstrating that DS resulted in a wider 378 therapeutic window using DS $(2.98 \pm 1.38 \text{ mA})$ compared to OS $(2.11 \pm 1.33 \text{ mA})$. 379 Moreover, DS (1.11 ± 1.00 mA) could reduce the current required to achieve symptom 380 relief compared to OS $(1.83 \pm 1.52 \text{ mA})$ (17). As with previous studies, a systematic 381 evaluation of non-motor symptoms was missing, and unlike our study, the outcome was 382 based on subjective clinical assessments using the ordinal UPDRS scale only. Also, the 383 384 stimulation titration protocols were not reported in the study, and presumably varied 385 across centers. And finally, like all studies to date that have systematically assessed directional STN-DBS, the TEED across stimulation conditions was not maintained for 386 longer periods. Moreover, the 3-months open-label observations had a fixed order (i.e., 387 388 OS period always prior to the DS period).

The present study aimed to address some limitations of previous studies investigating directional DBS. Namely, OS and DS were compared by complementing the subjective clinical evaluation by an objective assessment of muscular rigidity using EMG; furthermore, stimulation parameter titration was performed using small increments in the current amplitudes for both stimulation conditions; and finally, TEED, and thereby battery power consumption, was maintained for three weeks for each condition, when comparing OS and DS.

In the present study, DS and OS had no significant differences with regard to motor symptoms in both clinical and EMG-based measures, when controlling for the abovementioned confounding factors. However, OS had (non-significantly) better clinical effects than DS on all motor and non-motor measures apart from the cognitive evaluation (see below). These differences between OS and DS were more apparent in the chronic (3 weeks) than in the acute (30 minutes) evaluation settings.

Specifically, the UPDRS III score (39.63 ± 12.92 in the Stim OFF condition) improved with OS (30.00 ± 13.55 ; p=.001) and DS (30.72 ± 10.87 ; p=.003) in the acute assessment. In the chronic setting, UPDRS III improved even further with OS ($28.63 \pm$ 12.91), while it deteriorated with DS (32.42 ± 15.07); notably, the average difference (28.63 ± 12.91 vs. 32.42 ± 15.07) between conditions crossed the 3.25-point threshold for a minimal clinically important difference (MCID) of the UPDRS III (49), even though this difference was not significant due to the large variability within each condition.

Similarly, FoG-AC (17.83 \pm 15.05 in the Stim OFF condition) improved with both OS (14.83 \pm 13.66; p=.021) and DS (13.92 \pm 13.32; p=.024) in the acute assessment, and even further in the chronic setting (OS: 11.47 \pm 13.02; DS: 12.80 \pm 13.80).

These observations were complemented by the fact that in 3 of 19 patients, the electrical energy of DS needed to be increased during the chronic/long-term period above and beyond the estimated TEED to reach the therapeutic motor benefits of OS. These findings indicate that long-term assessments are necessary to capture the overall benefit of different programming approaches.

The cognitive long-term assessment revealed an exception and the only difference 417 between the stimulation conditions favoring DC; namely, DS led to (non-significantly) 418 higher MOCA scores, i.e., less cognitive impairment, as compared to OS (27.83 ± 1.92 419 vs. 26.53 ± 3.15 ; p=.080). Despite the small effect size, this observation warrants further 420 investigations in future due to different considerations: This finding was the only one in 421 favour of DS, and thereby in contrast to the above-mentioned overall trend of the other 422 motor and non-motor findings in favour of OS. Moreover, this MOCA change in PD 423 424 patients is not to be expected within the short six weeks evaluation period (50). Furthermore, the observed effect was driven by a deterioration of the MOCA sub-score 425 for executive function (OS vs. DS: 3.89 ± 1.05 vs. 4.47 ± 0.84; p=.071; OS vs. 426 preoperative baseline: 3.89 ± 1.05 vs. 4.63 ± 0.60 ; p=.015), which was previously 427 428 shown to be particularly affected by STN-DBS (51).

This stimulation-induced impact on executive function may be explained by the different 429 430 volumes of tissue activated (VTA) by OS vs. DS. Specifically, computational modeling suggested that TEED-balanced DS, i.e., applying about 30% less stimulation amplitude 431 with DS than OS (like in the present study), reduced the total VTA by 15% (28). This 432 reduced the coverage of the targeted and non-targeted volumes in the STN leading to 433 less motor benefits and less side effects regarding executive function, respectively. 434 However, these interpretations remain speculative since the clinical differences between 435 the OS and DS conditions did not reach statistical significance. 436

437 Limitations and considerations

438 While we attempted to control as many conditions as possible to achieve an impartial and highly systematic comparison between DS and OS, this study is not without 439 limitations. It must first be acknowledged that the sample size of our study is 440 441 comparable to other single center studies but far smaller than that of the multicenter PROGRESS study. However, one advantage of our study is that each patient 442 underwent a consistent and highly scrutinous procedure for stimulation programing and 443 parameter titration using small current intensity increments for both stimulation 444 conditions. 445

Moreover, the EMG activity recorded in our study provided an objective measure, but may have missed differences between conditions due to much variability between data points caused by some variability of electrode placements across evaluations. Nevertheless, the results are congruent with the standard subjective ordinal scalebased evaluations in this study, e.g., the UPDRS III scores.

451 Finally, a very important consideration that is unique to this study is that the TEED was maintained across the two stimulation conditions. This means that the current intensity 452 453 used for DS was always lower than for OS, and lower than its own side effect threshold. While this did allow for an impartial comparison of the two conditions when taking into 454 455 consideration TEED and thus battery lifespan, it did not allow for the comparison of the two conditions at each of their respective maximum current intensities, i.e., activated 456 457 VTA. The current findings, therefore, suggest that DS even below the maximum tolerable settings can achieve similar therapeutic efficacy as OS, even though the OS 458 459 effects seemed (non-significantly) larger across measures. However, we are left with the guestion of whether DS at the maximum possible current intensity may have 460 produced superior clinical benefits in our cohort compared to OS. Finally, the 461 observation periods of 3 weeks for each condition might have been too short to 462 delineate even larger differences between the conditions. 463

464 **Conclusions**

There were no significant differences between OS and DS with regard to motor and non-motor outcome parameters when they were applied at the same TEED levels, i.e., with 30% less stimulation intensity of the latter. However, in some cases, the stimulation intensity of DS needed to be increased above and beyond the TEED-estimated value to reach the motor benefits of OS. Furthermore, OS scored (non-significantly) better than DS in all motor and non-motor measures apart from the cognitive evaluation, where OS led to a deterioration of executive functions.

Long-term observation periods beyond acute assessments are necessary to identify differences in overall treatment benefit. Future confirmatory studies with larger sample cohorts and longer follow-up periods need to investigate the potential outcome differences of OS and DS with regard to motor and cognitive functions.

476

478 Credit authorship contribution statement

479 Alireza Gharabaghi: Funding acquisition, Conceptualization, Project administration,
480 Writing – original draft.

Idil Cebi: Project administration, Investigation, Formal analysis, Writing – review &
editing.

483 Maximilian Scherer: Methodology, Investigation, Formal analysis, Writing – review &
484 editing.

485 Patrick Bookjans: Investigation, Formal analysis, Writing – review & editing.

486 Bastian Brunnett: Investigation, Formal analysis, Writing – review & editing.

487 Luka Milosevic: Investigation, Formal analysis, Methodology, Writing – original draft.

488 Daniel Weiss: Funding acquisition, Conceptualization, Writing – review & editing.

489

490 Funding

This investigator-initiated trial was supported by Abbott / St. Jude Medical (SANTOP). The funding had no impact on the study design, on the collection, analysis and interpretation of data, on the writing of the report or on the decision to submit the article for publication.

495 Acknowledgements

A.G. was supported by the German Federal Ministry of Education and Research
(BMBF). M.S. was supported by the Alexander von Humboldt Foundation. D.W. was
supported by the German Research Council (WE5375/1-3) and the Michael J Fox
Foundation. We acknowledge support by the Open Access Publishing Fund of the
University of Tübingen.

501 **Declarations of competing interests**

A.G. was supported by research grants from Medtronic, Abbott, Boston Scientific, all of which were unrelated to this work. D. W. was supported by travel grants, speaker

- 504 honoraria and research grants from Abbott, Abbvie, Bial, Boston Scientific, Medtronic,
- 505 Kyowa Kirin, Stadapharm, all of which were unrelated to this work.

506 **References**

- 5071.Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, et al. A randomized trial508of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.
- Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21 Suppl 14:S290-304.
- 5123.Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation513for Parkinson's disease with early motor complications. N Engl J Med. 2013;368(7):610-22.
- 5144.Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, et al. Randomized trial of deep brain515stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012;79(1):55-65.
- 5. Lhommee E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, et al. Behavioural outcomes of
 subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's
 disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label
 randomised trial. Lancet Neurol. 2018;17(3):223-31.
- 520 6. Weiss D, Volkmann J, Fasano A, Kuhn A, Krack P, Deuschl G. Changing Gears DBS For 521 Dopaminergic Desensitization in Parkinson's Disease? Ann Neurol. 2021;90(5):699-710.
- 522 7. Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach WM, Krack P, et al. Cost523 effectiveness of neurostimulation in Parkinson's disease with early motor complications. Mov
 524 Disord. 2016;31(8):1183-91.
- 5258.Wodarg F, Herzog J, Reese R, Falk D, Pinsker MO, Steigerwald F, et al. Stimulation site within the526MRI-defined STN predicts postoperative motor outcome. Mov Disord. 2012;27(7):874-9.
- 5279.Bari AA, Fasano A, Munhoz RP, Lozano AM. Improving outcomes of subthalamic nucleus deep528brain stimulation in Parkinson's disease. Expert Rev Neurother. 2015;15(10):1151-60.
- Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H, et al. Long term effects of bilateral
 subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's
 disease. J Neurol Neurosurg Psychiatry. 2004;75(6):834-9.
- 532 11. Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, et al. Subthalamic
 533 nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease
 534 (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013;12(1):37-44.
- Rolston JD, Englot DJ, Starr PA, Larson PS. An unexpectedly high rate of revisions and removals
 in deep brain stimulation surgery: Analysis of multiple databases. Parkinsonism Relat Disord.
 2016;33:72-7.
- 53813.Contarino MF, Bour LJ, Verhagen R, Lourens MA, de Bie RM, van den Munckhof P, et al.539Directional steering: A novel approach to deep brain stimulation. Neurology. 2014;83(13):1163-5409.
- 54114.Pollo C, Kaelin-Lang A, Oertel MF, Stieglitz L, Taub E, Fuhr P, et al. Directional deep brain542stimulation: an intraoperative double-blind pilot study. Brain. 2014;137(Pt 7):2015-26.
- 54315.Dembek TA, Reker P, Visser-Vandewalle V, Wirths J, Treuer H, Klehr M, et al. Directional DBS544increases side-effect thresholds-A prospective, double-blind trial. Mov Disord.5452017;32(10):1380-8.
- 546 16. Steigerwald F, Muller L, Johannes S, Matthies C, Volkmann J. Directional deep brain stimulation
 547 of the subthalamic nucleus: A pilot study using a novel neurostimulation device. Mov Disord.
 548 2016;31(8):1240-3.
- 549 17. Schnitzler A, Mir P, Brodsky MA, Verhagen L, Groppa S, Alvarez R, et al. Directional Deep Brain
 550 Stimulation for Parkinson's Disease: Results of an International Crossover Study With
 551 Randomized, Double-Blind Primary Endpoint. Neuromodulation. 2022;25(6):817-28.

55218.Rosahl SK, Gharabaghi A, Liebig T, Feste CD, Tatagiba M, Samii M. Skin markers for surgical553planning for intradural lesions of the thoracic spine. Technical note. Surg Neurol.5542002;58(5):346-8.

- Southwell DG, Narvid JA, Martin AJ, Qasim SE, Starr PA, Larson PS. Comparison of Deep Brain
 Stimulation Lead Targeting Accuracy and Procedure Duration between 1.5- and 3-Tesla
 Interventional Magnetic Resonance Imaging Systems: An Initial 12-Month Experience. Stereotact
 Funct Neurosurg. 2016;94(2):102-7.
- 55920.Naros G, Grimm F, Weiss D, Gharabaghi A. Directional communication during movement560execution interferes with tremor in Parkinson's disease. Mov Disord. 2018;33(2):251-61.
- 56121.Milosevic L, Scherer M, Cebi I, Guggenberger R, Machetanz K, Naros G, et al. Online Mapping562With the Deep Brain Stimulation Lead: A Novel Targeting Tool in Parkinson's Disease. Mov563Disord. 2020;35(9):1574-86.
- 56422.Milian M, Luerding R, Ploppa A, Decker K, Psaras T, Tatagiba M, et al. "Imagine your neighbor565mows the lawn": a pilot study of psychological sequelae due to awake craniotomy: clinical566article. J Neurosurg. 2013;118(6):1288-95.
- Weiss D, Breit S, Wachter T, Plewnia C, Gharabaghi A, Kruger R. Combined stimulation of the
 substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait
 disturbance in Parkinson's disease. J Neurol. 2011;258(6):1183-5.
- 570 24. Kramme J, Dembek TA, Treuer H, Dafsari HS, Barbe MT, Wirths J, et al. Potentials and Limitations
 571 of Directional Deep Brain Stimulation: A Simulation Approach. Stereotact Funct Neurosurg.
 572 2021;99(1):65-74.
- 573 25. Mishra A, Unadkat P, McBriar JD, Schulder M, Ramdhani RA. An Institutional Experience of 574 Directional Deep Brain Stimulation and a Review of the Literature. Neuromodulation. 2023.
- Ramanathan PV, Salas-Vega S, Shenai MB. Directional Deep Brain Stimulation-A Step in the Right
 Direction? A Systematic Review of the Clinical and Therapeutic Efficacy of Directional Deep Brain
 Stimulation in Parkinson Disease. World Neurosurg. 2023;170:54-63 e1.
- 578 27. Merola A, Singh J, Reeves K, Changizi B, Goetz S, Rossi L, et al. New Frontiers for Deep Brain
 579 Stimulation: Directionality, Sensing Technologies, Remote Programming, Robotic Stereotactic
 580 Assistance, Asleep Procedures, and Connectomics. Front Neurol. 2021;12:694747.
- 58128.Rebelo P, Green AL, Aziz TZ, Kent A, Schafer D, Venkatesan L, et al. Thalamic Directional Deep582Brain Stimulation for tremor: Spend less, get more. Brain Stimul. 2018;11(3):600-6.
- 58329.Levin J, Krafczyk S, Valkovic P, Eggert T, Claassen J, Botzel K. Objective measurement of muscle584rigidity in Parkinsonian patients treated with subthalamic stimulation. Mov Disord.5852009;24(1):57-63.
- 58630.Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson's587disease with deep brain stimulation. Lancet Neurol. 2012;11(5):429-42.
- 588 31. Foltynie T, Zrinzo L, Martinez-Torres I, Tripoliti E, Petersen E, Holl E, et al. MRI-guided STN DBS in
 589 Parkinson's disease without microelectrode recording: efficacy and safety. J Neurol Neurosurg
 590 Psychiatry. 2011;82(4):358-63.
- Hutchison WD, Allan RJ, Opitz H, Levy R, Dostrovsky JO, Lang AE, et al. Neurophysiological
 identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol.
 1998;44(4):622-8.
- 59433.Koss AM, Alterman RL, Tagliati M, Shils JL. Calculating total electrical energy delivered by deep595brain stimulation systems. Ann Neurol. 2005;58(1):168; author reply -9.
- 59634.Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement597Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-598UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70.

599 35. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical 600 interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord. 1999;14(4):572-84.

60136.Ziegler K, Schroeteler F, Ceballos-Baumann AO, Fietzek UM. A new rating instrument to assess602festination and freezing gait in Parkinsonian patients. Mov Disord. 2010;25(8):1012-8.

- 60337.Hershey T, Craft S, Glauser TA, Hale S. Short-term and long-term memory in early temporal lobe604dysfunction. Neuropsychology. 1998;12(1):52-64.
- 405 38. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's
 406 disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci.
 407 2003;23(15):6351-6.
- 60839.Kaufman DA, Bowers D, Okun MS, Van Patten R, Perlstein WM. Apathy, Novelty Processing, and609the P3 Potential in Parkinson's Disease. Front Neurol. 2016;7:95.

610 40. Mathis S, Neau JP, Pluchon C, Fargeau MN, Karolewicz S, Iljicsov A, et al. Apathy in Parkinson's 611 disease: an electrophysiological study. Neurol Res Int. 2014;2014:290513.

Vukelic M, Gharabaghi A. Self-regulation of circumscribed brain activity modulates spatially
selective and frequency specific connectivity of distributed resting state networks. Front Behav
Neurosci. 2015;9:181.

615 42. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and
616 application of a Parkinson's disease quality of life questionnaire and its associated measures. J
617 Neurol. 1998;245 Suppl 1:S10-4.

618 43. Beck A. T. SR. Manual for the Beck Depression Inventory. Psychological Corporation, San
619 Antonio, TX; 1987.

44. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal
Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr
Soc. 2005;53(4):695-9.

45. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability,
validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci.
1992;4(2):134-9.

46. Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, Defebvre L. The Lille apathy rating scale
(LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 2006;77(5):579-84.

62947.Maier F, Lewis CJ, Eggers C, Kuhn AA, Krug H, Volkmann J, et al. Development and validation of630the deep brain stimulation impairment scale (DBS-IS). Parkinsonism Relat Disord. 2017;36:69-75.

48. Rammo RA, Ozinga SJ, White A, Nagel SJ, Machado AG, Pallavaram S, et al. Directional
Stimulation in Parkinson's Disease and Essential Tremor: The Cleveland Clinic Experience.
Neuromodulation. 2022;25(6):829-35.

Horvath K, Aschermann Z, Acs P, Deli G, Janszky J, Komoly S, et al. Minimal clinically important
difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord.
2015;21(12):1421-6.

637 50. Lessig S, Nie D, Xu R, Corey-Bloom J. Changes on brief cognitive instruments over time in
638 Parkinson's disease. Mov Disord. 2012;27(9):1125-8.

63951.Bucur M, Papagno C. Deep Brain Stimulation in Parkinson Disease: A Meta-analysis of the Long-640term Neuropsychological Outcomes. Neuropsychol Rev. 2023;33(2):307-46.